| abstract |
PCT No. PCT/JP94/00490 Sec. 371 Date Nov. 25, 1994 Sec. 102(e) Date Nov. 25, 1994 PCT Filed Mar. 25, 1994 PCT Pub. No. WO94/22845 PCT Pub. Date Oct. 13, 1994.Production of a benzothiazole compound of the formula (I) <IMAGE> (I) wherein R1 is a halogen atom, R2 and R3 may be the same or different and each is a hydrogen atom or a halogen atom, R4 is a hydrogen atom, a halogen atom, a lower alkyl, an alkoxy or an alkyl mercapto and R5 is a hydrogen atom or a lower alkyl, or a pharmaceutically acceptable salt thereof. The compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and have superior safety. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis. |